Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Accounts Payables (2016 - 2025)

Dare Bioscience (DARE) has disclosed Accounts Payables for 11 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 75.92% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Sep 2025, up 75.92%, and an annual FY2024 reading of $1.5 million, down 57.0% over the prior year.
  • Accounts Payables was $1.8 million for Q3 2025 at Dare Bioscience, up from $1.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $6.5 million in Q2 2023 and bottomed at $216043.0 in Q2 2021.
  • Average Accounts Payables over 5 years is $2.4 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Accounts Payables plummeted 87.4% in 2021, then skyrocketed 487.05% in 2023.
  • Year by year, Accounts Payables stood at $2.1 million in 2021, then fell by 3.57% to $2.0 million in 2022, then soared by 66.94% to $3.4 million in 2023, then crashed by 57.0% to $1.5 million in 2024, then increased by 26.72% to $1.8 million in 2025.
  • Business Quant data shows Accounts Payables for DARE at $1.8 million in Q3 2025, $1.8 million in Q2 2025, and $1.9 million in Q1 2025.